A Single-Cell Atlas of HR+ Breast Cancer Reveals the Shifting of the Tumor Microenvironment in Response to Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy (NAC) is the standard presurgery treatment for HR+ breast cancer (HR+ BC), but its response rate is frequently unsatisfactory, and the mechanism of chemoresistance and how NAC reshapes the immune microenvironment are still poorly understood. To investigate this question, the transcriptomes and spatial distribution patterns of cancer cells and immune cells from paired HR+ BC samples pre- and post-NAC were characterized with single-cell RNA sequencing (N=8) and multiplexed immunofluorescence staining (N=21). Overall design: Single-cell expression profiling of the HR+ breast cancer in pre- and post-treatment patients. For data usage terms and conditions, please contact the principle investigator.